Pharmaceutical Technology on MSN

Eisai and Biogen report Leqembi’s MHRA approval for Alzheimer’s

E isai and Biogen have announced the UK Medicines and Healthcare products Regulatory Agency's (MHRA) approval for Leqembi ...

“LEQEMBI®” (lecanemab) IV Maintenance Dosing for the Treatment of Early Alzheimer’s Disease Approved in the United Kingdom

Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, “Eisai”) and Biogen Inc. (Nasdaq: BIIB, Corporate headquarters: ...
Becker's Hospital Review

Biogen’s Alzheimer’s drug slowed cognitive decline by 27%

Following Biogen’s recent failure of Aduhelm and a CEO resignation on the horizon, the drugmaker’s new Alzheimer’s drug candidate showed promising results in a phase 3 trial with a 27 percent slower ...
Becker's Hospital Review

What Biogen’s Alzheimer’s drug win means

Biogen and Tokyo-based pharmaceutical company Eisai’s Alzheimer’s drug, which recently scored a win in a phase 3 trial by slowing cognitive decline by 27 percent among mild disease patients, has the ...

Stifel lifts Biogen to Buy, sees potential Alzheimer’s narrative shift

Stifel upgraded Biogen (NASDAQ: BIIB) to Buy from Hold in a note Thursday, raising its price target to $202 from $144, saying the stock’s risk/reward profile is improving ahead of multiple clinical ...
NBC New York

Biogen beats expectations, hikes outlook as Alzheimer's drug Leqembi and other new products gain traction

Biogen on Thursday reported second-quarter earnings and revenue that topped estimates and hiked its full-year guidance, as the company's cost cuts showed progress and sales of its breakthrough ...
Nasdaq

Eisai and Biogen Provide Update on Lecanemab Regulatory Review for Alzheimer’s Disease in the European Union

Eisai and Biogen update on lecanemab's EU regulatory review for early Alzheimer’s disease treatment following positive CHMP opinion. Eisai Co., Ltd. and Biogen Inc. have provided an update on the ...
NBC New York

Why Biogen's Alzheimer's Drug Aduhelm Is So Controversial

The U.S. Food and Drug Administration's approval of Biogen's Alzheimer's drug Aduhelm in June was heralded as a historic triumph in the fight against a disease that kills thousands of Americans every ...
KTVU

FDA approves much-debated Alzheimer’s drug Biogen, 1st in nearly 20 years

WASHINGTON - Government health officials on Monday approved the first new drug for Alzheimer’s disease in nearly 20 years, disregarding warnings from independent advisers that the much-debated ...
Nasdaq

Biogen’s Investigational Tau-Targeting Therapy BIIB080 Receives FDA Fast Track Designation for the Treatment of Alzheimer’s Disease

CAMBRIDGE, Mass., April 02, 2025 (GLOBE NEWSWIRE) -- Biogen Inc. (Nasdaq: BIIB) today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation to BIIB080, an ...

What the Options Market Tells Us About Biogen

Analyzing the Volume and Open Interest in these contracts, it seems that the big players have been eyeing a price window from ...
Zacks Investment Research on MSN

Shine a Light on Healthcare ETFs Amid National Alzheimer's Awareness Month

November marks National Alzheimer’s Disease Awareness Month in the United States, serving as a crucial reminder of the millions affected by the disease. This observance, established in 1983, has ...